Sign in
MOR Stock Price, Chart, Stats & News
MorphoSys AG
Save
MorphoSys AG (MOR) does not currently pay a dividend.
2.86B
Market cap
–
Current P/E
–
Forward P/E
MOR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 75.51% |
Operating margin | -105.96% |
Pretax margin | -80.13% |
Net margin | -79.63% |
Effective tax rate | 0.62% |
ROA | -9.36% |
ROE | -183.80% |
D/E | 12.97x |
Interest coverage ratio | -2.30x |
MOR valuation
P/E | – |
P/S | 10.39x |
P/B | 45.98x |
P/CF | -7.62x |
P/FCF | -8.29x |
P/OCF | -7.62x |
PEG | -0.14x |
EV multiple | -20.44x |
About
MorphoSys AG is a commercial-stage biopharmaceutical company dedicated to the discovery, advancement, and marketing of innovative therapeutic antibodies aimed at treating cancer and autoimmune disorders. While its commercial operations are primarily situated in the United States, its development and partnership activities span globally. A key commercial offering is Tafasitamab, an antibody prescribed for various B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
Similar securities
Based on sector and market capitalization
Report issue